Abstracts tagged "Disease Activity"

Abstract Number: L09 • ACR Convergence 2024
Efficacy and Safety of Tofacitinib in Patients with Active Systemic Juvenile Idiopathic Arthritis
Hermine Brunner¹, Caifeng Li², Kogie Chinniah³, Yosef Uziel⁴, Olga Synoverska⁵, Sujata Sawhney⁶, Inmaculada Calvo Penades⁷, Ingrid Clara Louw⁸, Meiping Lu⁹, Pooja Nikunj Patel¹⁰, Pamela F. Weiss¹¹, Cheng Chang¹², Ivana Vranic¹³, Shixue Liu¹⁴, Annette Diehl¹⁵, Jose L. Rivas¹⁶, Carol A. Connell¹⁷, Gary G. Koch¹⁸, Alberto Martini¹⁹, Daniel J. Lovell¹, Nicolino Ruperto²⁰ and the PRINTO and PRCSG investigators, ¹Cincinnati Children’s Hospital Medical Center, and University of Cincinnati, Cincinnati, OH, ²Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Bejing, China, ³Department of Paediatrics and Child Health, University of Kwa-Zulu, and Enhancing Care Foundation, Durban, South Africa, ⁴Pedriatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center and Israel Tel Aviv University School of Medicine, Kfar Saba, Israel, ⁵Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine, ⁶Sir Ganga Ram Hospital, New Delhi, India, ⁷Hospital Universitario y Politécnico La Fe, Valencia, Spain, ⁸Panorama Medical Centre, Cape Town, South Africa, ⁹Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China, ¹⁰Ann & Robert H. Lurie Children’s Hospital of Chicago; Northwestern University School of Medicine, Chicago, IL, ¹¹Division of Rheumatology, Children's Hospital of Philadelphia, and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ¹²Pfizer Inc, New York, NY, ¹³Pfizer Ltd, Tadworth, United Kingdom, ¹⁴Pfizer Inc, Shanghai, China, ¹⁵Pfizer Inc, Collegeville, PA, ¹⁶Pfizer SLU, Madrid, Spain, ¹⁷Pfizer Inc, Groton, CT, ¹⁸University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹⁹University of Genoa, Genoa, Italy, ²⁰Università Milano Bicocca, Milano, and IRCCS Fondazione San Gerardo dei Tintori, Monza, Italy
Background/Purpose: Tofacitinib (TOF) has been shown to be efficacious in the treatment of polyarticular course JIA, including systemic JIA (sJIA) without active systemic features. Here…
Abstract Number: 0043 • ACR Convergence 2024
Inflammatory and Angiogenic Serum Profile of Refractory Rheumatoid Arthritis
Manon Lesturgie-Talarek¹, Virginie Gonzalez², ALICE COMBIER³, Marion THOMAS⁴, Margaux Boisson⁵, Sandrine Carves³, Sarah Wanono³, Lucie Poiroux³, Anne Cauvet¹, Sophie Hecquet⁶, Yannick Allanore⁷ and Jérôme Avouac⁸, ¹Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, ²Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, Ile-de-France, France, ³Hôpital Cochin - Université Paris Cité, Paris, France, ⁴APHP, Paris, France, ⁵Hôpital Cochin - Université Paris Cité, Paris, ⁶Cochin Hospital, Paris, France, ⁷Université Paris Cité, Paris, France, ⁸Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Despite the emergence of new therapies, a considerable proportion of individuals with rheumatoid arthritis (RA) still endure symptoms, giving rise to the concept of…
Abstract Number: 0500 • ACR Convergence 2024
An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderate to Severe Active Rheumatoid Arthritis over a Median of 4.3 Years
Kevin Winthrop¹, Daniel Aletaha², Roberto Caporali³, Yoshiya Tanaka⁴, Tsutomu Takeuchi⁵, Vikas Modgill⁶, Edmund V. Ekoka Omoruyi⁷, Dick de Vries⁸, Katrien Van Beneden⁹, Jacques-Eric Gottenberg¹⁰ and Gerd Burmester¹¹, ¹School of Medicine, Oregon Health and Science University, Portland, OR, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria, ³Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁴Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁵Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁶Medical Safety, Galapagos NV, Mechelen, Belgium, ⁷Biostatistics, Galapagos NV, Mechelen, Belgium, ⁸Clinical Development, Galapagos BV, Leiden, Netherlands, ⁹Medical Affairs, Galapagos NV, Mechelen, Belgium, ¹⁰Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ¹¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The oral Janus kinase 1-preferential inhibitor filgotinib (FIL) is approved at doses of 100 mg (FIL100) and 200 mg (FIL200) for the treatment of…
Abstract Number: 0599 • ACR Convergence 2024
Sex- related Differences in Efficacy of Biologics in Axial Spondyloarthritis: A Systematic Review and Meta-analysis
Haseeb Chaudhary¹, Omer Pamuk², Sarah Abi Doumeth³, Ansaam Daoud⁴, Muhammad Shamim⁵ and Marina Magrey⁶, ¹Case Western Reserve University, Westlake, OH, ²University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ³Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland Heights, OH, ⁴Case Western Reserve University/University Hospitals, Akron, OH, ⁵University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ⁶Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH
Background/Purpose: There is limited information about sex-related differences in efficacy of biologics in axial spondyloarthritis (axSpA). We hypothesized that females with axSpA are less likely…
Abstract Number: 0818 • ACR Convergence 2024
Defining BASDAI Cut-offs for Disease Activity States in Axial Spondylarthritis – Results from the EuroSpA Collaboration
Stylianos Georgiadis¹, Lykke Oernbjerg¹, Brigitte Michelsen², Tore K. Kvien³, Simon Horskjær Rasmussen⁴, Jakub Závada⁵, Kristýna Bubová⁶, Bente Glintborg⁷, Anne Gitte Loft⁸, Ana Maria Rodrigues⁹, Maria Jose Santos¹⁰, Adrian Ciurea¹¹, Michael Nissen¹², Laura Kuusalo¹³, Jarno Rutanen¹⁴, Ziga Rotar¹⁵, Katja Perdan-Pikmajer¹⁵, Bjorn Gudbjornsson¹⁶, Olafur Palsson¹⁷, Daniela DiGuiseppe¹⁸, Mikkel Ostergaard¹⁹ and Merete Hetland²⁰, ¹Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ²Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, ³Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁴Rigshospitalet Glostrup, Glostrup, Denmark, ⁵Institute of Rheumatology and Charles University, Praha, Czech Republic, ⁶Institute of Rheumatology and Charles University, Prague, Czech Republic, ⁷DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ⁸Aarhus University Hospital and Aarhus University, Horsens, Denmark, ⁹Nova Medical School and Hospital dos Lusíadas, Lisbon, Portugal, ¹⁰Hospital Garcia de Orta and Centro Académico de Medicina de Lisboa, Lisboa, Portugal, ¹¹University Hospital Zurich, Zürich, Switzerland, ¹²Geneva University Hospital, Geneva, Switzerland, ¹³University of Turku and Turku University Hospital, Turku, Finland, ¹⁴Tampere University Hospital, Tampere, Finland, ¹⁵University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹⁶Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹⁷University of Iceland and Skåne University Hospital, Reykjavik, Iceland, ¹⁸Karolinska Institutet, Stockholm, ¹⁹Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ²⁰Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark
Background/Purpose: While the Axial Spondyloarthritis Disease Activity Score based on C-reactive protein (ASDAS) is recommended for assessment of disease activity in patients with axial spondyloarthritis…
Abstract Number: 1263 • ACR Convergence 2024
Assessing Lupus Low Disease Activity State in the Pediatric Rheumatology Clinic: Baseline Data Collection from a Pediatric Lupus Collaborative
Emily Smitherman¹, Julia Harris², Aimee Hersh³, Jennifer Huggins⁴, Ashley Lytch⁵, Hanh Ho⁶, Ashley Meyer⁷, Megan Quinlan-Waters⁴, Livie Timmerman⁸ and Jon Burnham⁹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Children's Mercy Kansas City, Overland Park, KS, ³University of Utah, Salt Lake City, UT, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Children's Mercy Hospital, Kansas City, MO, ⁶Children's Mercy Kansas City, Kansas City, ⁷Children's Hospital of Philadelphia, Philadelphia, ⁸University of Alabama at Birmingham, Gardendale, AL, ⁹Children's Hospital of Philadelphia, Bryn Mawr, PA
Background/Purpose: Achievement of a lupus low disease activity state (LLDAS) has been associated with less organ damage, fewer disease flares, and improved health-related quality of…
Abstract Number: 1364 • ACR Convergence 2024
Machine Learning-Driven Models for Disease Activity Prediction and Therapeutic Response Evaluation in Rheumatoid Arthritis Patients: An Analysis of Data from the Multicentre, Prospective, Egyptian Collage of Rheumatology (ECR) Study Group
Nevin Hammam¹, Tarek Nahool², A. M. Yasser³, Eman F Mohamed⁴, Samar Tharwat⁵, Doaa Mosad Mosa⁶, Maha Nassr⁷, Faten Ismail⁸, Rawhya R El Shereef⁸, Nora Y. Elsaid⁹, Osman Hammam¹⁰, Suzan S. Al‑Adle⁹ and Tamer A Gheita¹¹, ¹Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, Boston, MA, ²University of the People, Pasadena, CA, USA, Qena, Egypt, ³Physics Department, Faculty of Science, South Valley University, Qena, Egypt; Alchemy Research, Alchemy Global Solutions, Abu Dhabi, UAE, Abu Dhabi, United Arab Emirates, ⁴Internal Medicine Department, Rheumatology Unit, Faculty of Medicine (Girls), Al-Azhar University, Cairo, Egypt, ⁵Rheumatology Unit, Internal Medicine, Mansoura University, Dakahlia, ⁶Rheumatology & Rehabilitation Department, Mansoura University Hospitals, Mansoura University Faculty of Medicine, Egypt, Dakahlia, Egypt, ⁷Rheumatology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt, Fayoum, Egypt, ⁸Rheumatology Department, Faculty of Medicine, Minia University, Minia, Egypt, ⁹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ¹⁰Department of Rheumatology and Rehabilitation, Faculty of Medicine, New Valley University, New Valley, Assiut, Egypt, ¹¹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
Background/Purpose: Rheumatoid arthritis (RA) often exhibits fluctuating and challenging-to-assess clinical courses that lead to irreversible joint destruction. However, a "Treat-to-Target" strategy is recommended aiming to…
Abstract Number: 1499 • ACR Convergence 2024
Outcome of Newly Onset SLE with Neuropsychiatric Symptoms and Its Clinical Features in Daily Clinical Practice: A Single Center Study
Shuzo Sato, Fumitaka Seike, Yuya Sumichika, Kenji Saito, Shuhei Yoshida, Haruki Matsumoto, Jumpei Temmoku, Yuya Fujita, Naoki Matsuoka and Tomoyuki Asano, Fukushima Medical University, Fukushima, Fukushima, Japan
Background/Purpose: Although neuropsychiatric (NP) symptoms may occur in patients with SLE even in initial onset, studies regarding the distinct clinical features of SLE patients with…
Abstract Number: 1811 • ACR Convergence 2024
The Immune Map of Lupus Nephritis: A Spatially Resolved Kidney Proteomic Approach
Chen-Yu Lee¹, Matthew Caleb Marlin², Xiaoping Yang¹, Alessandra Ida Celia³, Vasileios Morkotinis⁴, Richard Furie⁵, Jill Buyon⁶, Chaim Putterman⁷, Jennifer Barnas⁸, Kenneth Kalunian⁹, Peter Izmirly¹⁰, Betty Diamond¹¹, Anne Davidson¹², Diane Kamen¹³, Jeff Hodgin¹⁴, the Accelerating Medicines Partnership RA/SLE¹⁵, Judith James², Michelle Petri¹⁶, Joel Guthridge², Avi Rosenberg¹ and Andrea Fava¹, ¹Johns Hopkins UNiversity, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Sapienza University of Rome, Rome, Italy, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Northwell Health, Manhasset, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Albert Einstein College of Medicine, Safed, Israel, ⁸University of Rochester, Rochester, NY, ⁹University of California San Diego, La Jolla, CA, ¹⁰New York University Grossman School of Medicine, New York, NY, ¹¹The Feinstein Institutes for Medical Research, Manhasset, NY, ¹²Feinstein Institutes for Medical Research, Manhasset, NY, ¹³Medical University of South Carolina, Charleston, SC, ¹⁴University of Michigan, Michigan, ¹⁵multiple, multiple, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Treatment response rates in lupus nephritis (LN) remain suboptimal, highlighting the need for a better understanding of LN pathogenesis to enhance treatment strategies. Single-cell…
Abstract Number: 2238 • ACR Convergence 2024
The Effect of Inflammation on Cardiovascular Risk in Rheumatoid Arthritis Varies According to Sex and Anticitrullinated Protein Antibody Status
George Karpouzas¹, Piet Van RIel², Elena Myasoedova³, Miguel Angel Gonzalez-Gay⁴, alfonso Corrales-Martínez⁵, Solbritt Rantapaa-Dahlqvist⁶, Petros Sfikakis⁷, Patrick Dessein⁸, Linda Tsang⁹, Carol Hitchon¹⁰, Hani El Gabalawy¹¹, Virginia Pascual Ramos¹², Irazu Contreras Yanez¹³, Iris Jazmín Colunga Pedraza¹⁴, Dionicio Galarza-Delgado¹⁵, jose Ramon Azpiri-Lopez¹⁶, Anne Grete Semb¹⁷, Durga P Misra¹⁸, Patrick Durez¹⁹, Brian Bridal Logstrup²⁰, Ellen Margrethe Hauge²¹, George Kitas²² and Sarah Ormseth²³, and ATACC-RA, ¹Harbor-UCLA Medical Center, Torrance, CA, ²Radboud University Medical Center, Nijmegen, Netherlands, ³Mayo Clinic, Rochester, MN, ⁴University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁶Umeå University, Umeå, Sweden, ⁷Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁸University of Witwatersrand, Johannesburg, South Africa, ⁹University of Witwatersrand, Johanessburg, South Africa, ¹⁰University of Mannitoba, Winnipeg, Canada, ¹¹University of Mannitoba, Winnipeg, MB, Canada, ¹²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, ¹³Instituto Nacional de las Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹⁴Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁵UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ¹⁶Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁷Diakonhjemmet Hospital, Oslo, Norway, ¹⁸Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁹UCLouvain, Louvain, Belgium, ²⁰University of Aarhus, Aarhus, Denmark, ²¹Aarhus Universitetshospital, Aarhus, Denmark, ²²The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom, ²³The Lundquist Institute, Torrance, CA
Background/Purpose: Disease activity associated with cardiovascular (CV) risk in rheumatoid arthritis (RA). Females with RA exhibit higher disease activity than males. Yet, males with RA…
Abstract Number: 2380 • ACR Convergence 2024
Characterizing SLE Patients into Type 1 and Type 2 Disease States: Insights from a Single Lupus Cohort
Angela Hu¹, Lauren Erdman², Dennisse Bonilla³, Qixuan Li³, Laura Patricia Whittall Garcia³, Dafna Gladman⁴ and Zahi Touma⁵, ¹University of British Columbia, Vancouver, BC, Canada, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: It has been proposed that SLE may be divided into Type 1 and Type 2 states. Type 1 manifestations are well captured in disease…
Abstract Number: 0052 • ACR Convergence 2024
Single Cell RNA-sequencing Analysis Revealed Peripheral Blood and Synovial Alterations of Dendritic Cells in Rheumatoid Arthritis
Yuichi Suwa¹, Saeko Yamada¹, Toshiyuki Ushijima², Hideyuki Takahashi², Tomohisa Okamura¹, Yasuo Nagafuchi³ and Keishi Fujio⁴, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Japan., Bunkyo, Tokyo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Japan., Bunkyo-ku, Tokyo, Japan, ³Department of Functional Genomics and Immunological Diseases, Graduate Schoold of Medicine, the University of Tokyo, Tokyo, Japan, ⁴Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Bunkyo, Tokyo, Japan
Background/Purpose: Recent single cell analyses have unveiled novel dendritic cell (DC) subpopulations that could potentially be linked to rheumatoid arthritis (RA). This study aimed to…
Abstract Number: 0506 • ACR Convergence 2024
24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis: The 2024 Interim Report
Takao Fujii¹, Nami Okamoto², Asami Abe³, Michiaki Takagi⁴, Nobunori Takahashi⁵, Atsuo Nakajima⁶, Ayako Nakajima⁷, Shingo Nakayamada⁸, Keiichiro Nishida⁹, Takeshi Kawaberi¹⁰, Naomi Sunaga¹⁰, Yuki Tsujita¹¹, Sumi Chonan¹², Masataka Kuwana¹³ and Yoshiya Tanaka¹⁴, ¹Wakayama Medical University, Wakayama, Japan, ²Osaka Rosai Hospital, Sakai-city, Osaka, Japan, ³Niigata Rheumatic Center, Shibata, Japan, ⁴Yamagata University Faculty of Medicine, Yamagata, Japan, ⁵Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁶Ueno Dialysis Clinic, Tokyo, Japan, ⁷Center for Rheumatic Diseases, Mie University Hospital, Mie, Japan, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health Japan,, Kitakyushu, Japan, ⁹Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ¹⁰Abbvie GK, Minato-Ku, Tokyo, Japan, ¹¹AbbVie, Minato City Tokyo, Japan, ¹²Abbvie GK, Tokyo, Japan, ¹³Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹⁴Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
Background/Purpose: Upadacitinib (UPA) was approved in 2020 in Japan for "the treatment of Rheumatoid arthritis (RA) with inadequate response to conventional therapy (including inhibition of…
Abstract Number: 0601 • ACR Convergence 2024
Early Improvement of Pain, Long-Term Disease Control, and Quality of Life Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib
Peter C. Taylor¹, Lihi Eder², Yael Klionsky³, Fabian Proft⁴, Thomas Iyile⁵, Erin Mancl⁶, Priscila Magalhaes Reis Nakasato⁷, Xiaolan Ye⁸, Limei Zhou⁶ and Philip Mease⁹, ¹University of Oxford, Oxford, United Kingdom, ²University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, ³Division of Rheumatology, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵AbbVie Inc., hyattsville, MD, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., Randolph, NJ, ⁸AbbVie Inc., Mettawa, IL, ⁹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA

Background/Purpose: Severe musculoskeletal manifestations of PsA, particularly joint pain, can result in reduced physical function, decreased quality of life, and progressive and irreversible joint damage.1,2…
Abstract Number: 0828 • ACR Convergence 2024
Efficacy of Eosinophil-Targeting Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis in the Phase 3 MANDARA Trial
Peter Merkel¹, David Jayne², Ulrich Specks³, Christian Pagnoux⁴, Benjamin Terrier⁵, Bernhard Hellmich⁶, Sofia Necander⁷, Anat Shavit⁸, Claire Walton⁹ and Michael Wechsler¹⁰, ¹University of Pennsylvania, Philadelphia, PA, ²University of Cambridge, Cambridge, United Kingdom, ³Mayo Clinic, Rochester, MN, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ⁶Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁷Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁸BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ⁹Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁰National Jewish Health, Denver, CO
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by small- to medium-vessel vasculitis, asthma and eosinophilia. In the head-to-head MANDARA trial…

1
2
3
…
102
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].